Fluoroestradiol F 18

2023 年，中国科学的投入与产出持续向好，继续书写新篇章。根据国家统计局、科学技术部和财政部联合在今年 10 月发布的《全国科技经费投入统计公报》，2023 年中国研究与试验发展（R&D）经费投入保持稳定增长，投入强度持续提升。基础研究、应用研究和试验发展经费分别为 2259.1 亿元、3661.5 亿元和 27436.5 亿元，分别比上年增长 11.6%、5.1% 和 8.5%。 稳定的经济社会发展和持续增长的研发投入，为中国科学界的奋进创新提供了坚实支撑，注入了强大活力。中国科学家在国际知名全学科学术出版机构——细胞出版社（Cell Press）旗下期刊上的突出表现，展示了中国科学在研究活跃度、学术影响力、开放共享等多个方面的优异表现。 01 稳步前进的中国科研 2023 年，中国学者研究产出数量持续提升，以中国机构为第一完成单位、发表在 Cell Press 细胞出版社旗下研究型期刊上的研究性论文数量继续快速增长， 总发文量突破了 2000 篇大关，较上一年增加了 52.8%，是 2018 年发表量的近 5 倍。 从学科分布来看，2023 年中国学者在交叉科学和生命科学领域的表现最为突出。交叉科学发文量突破 900 篇，生命科学发文量突破 600 篇，并且与 2022 年相比论文数量分别增加了 89.4% 和 49.5%，增幅显著。物质科学领域也稳中有进，发文量从上一年的 419 篇增长至 436 篇；更值得一提的是，中国学者在医学领域的表现日益突出，发文量达到了上一年的 2.88 倍。 科学的高速发展离不开高质量学术期刊提供的展示舞台。2023 年，细胞出版社旗下共有 14 本混合型期刊（hybrid journal）实现了中国论文发文量的增长。刊登在医学期刊 Med 的中国论文增幅最高，较上一年增加了 8 倍；此外，医学及生命科学领域的三本期刊 Immunity、Cell Systems 和 Cell Chemical Biology 的中国论文增幅均突破了 100%。 值得关注的是，2023 年中国学者在 Cell 上发表的论文数量达到 47 篇，较上一年增加了 62% ；Cancer Cell增幅近40%。在旗舰期刊中， Immunity、Neuron、Developmental Cell 的发文增量均突破 20 篇。此外，中国学者还为细胞出版社 2023 年新推出的物质科学期刊 Device 贡献了 16 篇高质量论文。中国科研在各个领域全面开花，展现出了强劲的发展势头。 科学的进步建立在信任现有知识的基础之上。为建立这种信任，我们需要透明、易获取的科学信息。2023 年，中国科学家携手细胞出版社，继续为更加透明开放的学术交流添砖加瓦：与上一年相比，中国科学家在细胞出版社混合型期刊上、以开放获取（OA）形式发表的论文占比，从上一年的 68.9% 增加到 2023 年的 75%；论文篇数则增加了 91.7%。 2023 年，细胞出版社旗下 42 本混合型期刊均为作者提供了开放获取选项，同时继续保持期刊所代表的最高质量和严谨的编辑标准。其中既包括 Cell、Cancer Cell、Matter 等细胞出版社旗舰期刊，也包括 Med、 One Earth、Device 等近几年新设立的深耕各个领域的旗舰新期刊。 02 2023 中国年度论文 2023 年，第一完成单位为中国机构、发表在细胞出版社旗下期刊的论文突破了 2000 篇大关。经细胞出版社编辑部提名、第三方专家委员会的独立评审，并综合论文下载量、引用量和领域内突破性等权衡标准，最终评选出了生命科学领域、物质科学领域、医学领域、交叉学科领域和可持续发展五个领域的“细胞出版社 2023 中国年度论文”共 40 篇（医学、可持续科学领域各 5 篇，其他 3 个领域各 10 篇）。另经网友投票，评出“细胞出版社 2023 年度最受欢迎中国论文”共 25 篇（每个领域 5 篇）。 获奖作者可扫描右侧二维码至中国科学家微站，领取获奖证书，并参与有奖互动！ 细胞出版社 2023 中国年度论文 生命科学 上下滑动查看全部论文 （排名不分先后，仅展示主要通讯作者及其单位） 1. Antagonistic RALF peptides control an intergeneric hybridization barrier on Brassicaceae stigmas Cell 瞿礼嘉（北京大学） 2. Epithelial cells activate fibroblasts to promote esophageal cancer development Cancer Cell 吴晨（中国医学科学院/北京协和医学院肿瘤医院） 3. Exhaustion-associated cholesterol deficiency dampens the cytotoxic arm of antitumor immunity Cancer Cell 许琛琦（国科大杭州高等研究院） 4. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy Cell Metabolism 邵志敏（复旦大学肿瘤研究所） 5. Hepatic soluble epoxide hydrolase activity regulates cerebral Aβ metabolism and the pathogenesis of Alzheimer’s disease in mice Neuron 朱心红（深圳大学） 6. Live birth of chimeric monkey with high contribution from embryonic stem cells Cell 刘真（中国科学院脑科学与智能技术卓越创新中心） 7. Microglial Piezo1 senses Aβ fibril stiffness to restrict Alzheimer’s disease Neuron 莫玮（厦门大学） 8. Neural mechanism underlying depressive-like state associated with social status loss Cell 胡海岚（浙江大学） 9. NF-κB activation enhances STING signaling by altering microtubule-mediated STING trafficking Cell Reports 张从刚（清华大学） 10. Prolonged sleep deprivation induces a cytokine-storm-like syndrome in mammals Cell 张二荃（北京生命科学研究所） 细胞出版社 2023 中国年度论文 物质科学 上下滑动查看全部论文 （排名不分先后，仅展示主要通讯作者及其单位） 1. A general approach to high-entropy metallic nanowire electrocatalysts Matter 郭少军（北京大学） 2. Completely stereospecific synthesis of a molecular cinquefoil (51) knot Chem 张亮（华东师范大学） 3. Dual single-atom catalyst design to build robust oxygen reduction electrode via free radical scavenging Chem Catalysis 邢巍（中国科学院长春应用化学研究所） 4. Eliminating over-oxidation of ruthenium oxides by niobium for highly stable electrocatalytic oxygen evolution in acidic media Joule 孙晓明（北京化工大学） 5. Enhancing the electrochemical reduction of carbon dioxide to multi-carbon products on copper nanosheet arrays via cation-catalyst interaction CRPS 范战西（香港城市大学） 6. High-strength and ultra-tough whole spider silk fibers spun from transgenic silkworms Matter 孟清（东华大学） 7. Modular photoredox system with extreme reduction potentials based on pyridine catalysis Chem 焦雷（清华大学） 8. Passive thermal management of electronic devices using sorption-based evaporative cooling Device 王如竹（上海交通大学） 9. Scalable and durable Janus thermal cloak for all-season passive thermal regulation Device 崔可航（上海交通大学） 10. Unlocking cycling longevity in micro-sized conversion-type FeS2 cathodes Joule 李泓（天目湖先进储能技术研究院） 细胞出版社 2023 中国年度论文 医  学 上下滑动查看全部论文 （排名不分先后，仅展示主要通讯作者及其单位） 1. Determining a multimodal aging clock in a cohort of Chinese women Med 刘光慧（中国衰老标志物研究联合体） 2. Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial Cancer Cell 赵维莅（上海交通大学医学院附属瑞金医院） 3. Orbitofrontal cortex-hippocampus potentiation mediates relief for depression: A randomized double-blind trial and TMS-EEG study Cell Reports Medicine 袁逖飞（国家精神疾病医学中心（上海市精神卫生中心）） 4. Rapid increasing burden of diabetes and cardiovascular disease caused by high body mass index in 1.25 million Chinese adults, 2005–2018 Med 王增武（中国医学科学院北京协和医学院） 5. Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309) Cancer Cell 张力（中山大学） 细胞出版社 2023 中国年度论文 交叉科学 上下滑动查看全部论文 （排名不分先后，仅展示主要通讯作者及其单位） 1. A hybrid deep forest-based method for predicting synergistic drug combinations Cell Reports Methods 伯晓晨（天津大学） 2. A robust protein-mimicking metallo-amine cage showing proton-driven allostery with water as the effector Chem 苏成勇（中山大学） 3. Adaptive evolution of the enigmatic Takakia now facing climate change in Tibet Cell 何奕騉（首都师范大学） 4. Biodegrading plastics with a synthetic non-biodegradable enzyme Chem 姜文君（中国农业大学） 5. BrainCog: A Spiking Neural Network based Brain-inspired Cognitive Intelligence Engine for Brain-inspired AI and Brain Simulation Patterns 曾毅（中国科学院自动化研究所） 6. Highly sensitive and extremely durable wearable e-textiles of graphene/carbon nanotube hybrid for cardiorespiratory monitoring iScience 赵仲（武汉纺织大学） 7. Integrated wearable smart sensor system for real-time multi-parameter respiration health monitoring CRPS 刘超然（杭州电子科技大学） 8. Learning protein fitness landscapes with deep mutational scanning data from multiple sources Cell Systems 郑明月（中国科学院上海药物研究所） 9. Plasma metabolic fingerprints for large-scale screening and personalized risk stratification of metabolic syndrome Cell Reports Medicine 卜军（上海交通大学医学院附属仁济医院） 10. Steering phase-separated droplets to control fibrillar network evolution of supramolecular peptide hydrogels Matter 闫学海（中国科学院过程工程研究所） 细胞出版社 2023 中国年度论文 可持续发展领域 上下滑动查看全部论文 （排名不分先后，仅展示主要通讯作者及其单位） 1. A synergistic approach to air pollution control and carbon neutrality in China can avoid millions of premature deaths annually by 2060 One Earth 张强（清华大学） 2. An updated global mercury budget from a coupled atmosphere-land-ocean model: 40% more re-emissions buffer the effect of primary emission reductions One Earth 张彦旭（南京大学） 3. Extreme salt-resisting multistage solar distillation with thermohaline convection Joule 徐震原（上海交通大学） 4. Global warming may significantly increase childhood anemia burden in sub-Saharan Africa One Earth 阚海东（复旦大学） 5. Robust strategies to end global poverty and reduce environmental pressures One Earth 郭钊侠（四川大学） 细胞出版社 2023 年度 最受欢迎中国论文 上下滑动查看全部论文 （排名不分先后，仅展示主要通讯作者及其单位） 生命科学 1. A HD-ZIP transcription factor specifies fates of multicellular trichomes via dosage-dependent mechanisms in tomato Developmental Cell 吴双（福建农林大学） 2. A receptor-like kinase controls the amplitude of secondary cell wall synthesis in rice Current Biology 张大兵 （上海交通大学） 3. Antifungal mechanisms of silver nanoparticles on mycotoxin producing rice false smut fungus iScience 寇艳君（中国水稻研究所） 4. Lactobacillus plantarum-derived indole-3-lactic acid ameliorates colorectal tumorigenesis via epigenetic regulation of CD8+ T cell immunity Cell Metabolism 刘星吟（南京医科大学） 5. Pregnancy-induced changes to the gut microbiota drive macrophage pyroptosis and exacerbate septic inflammation Immunity 龚神海（南方医科大学） 物质科学 1. 18.2%-efficient ternary all-polymer organic solar cells with improved stability enabled by a chlorinated guest polymer acceptor Joule 闵杰（武汉大学） 2. A method to prolong lithium-ion battery life during the full life cycle CRPS 朱建功（同济大学） 3. A Multi-Stimuli-Responsive Actuator for Efficient Thermal Management and Various Biomimetic Locomotion CRPS 刘建伟（中国科学技术大学） 4. Chameleon Inspired Flexible Photonic Crystal Lens Shaped Dynamic Pressure Sensor Based on Structural Color Shift CRPS 刘向阳（厦门大学） 5. Understanding human common driving semantics for autonomous vehicles Patterns 陈喜群（浙江大学） 医学 1. A robust and efficient AI assistant for breast tumor segmentation from DCE-MRI via a spatial-temporal framework Patterns 沈定刚（上海科技大学） 2. Exosome-based bone-targeting drug delivery alleviates impaired osteoblastic bone formation and bone loss in inflammatory bowel diseases Cell Reports Medicine 苏佳灿（上海大学） 3. RNA N6-methyladenosine methyltransferase METTL3 drives NAFLD-related hepatocellular carcinoma (HCC) and is a therapeutic target for boosting immunotherapy Cell Reports Medicine 于君（香港中文大学） 4. TRIM21 is a druggable target for the treatment of metastatic colorectal cancer through ubiquitination and activation of MST2 Cell Chemical Biology 吴华（苏州大学） 5. Tumor microenvironment-tailored nanoplatform for companion diagnostic applications of precise cancer therapy Chem 宋国胜（湖南大学） 交叉科学 1. Effective and efficient neural networks for spike inference from in vivo calcium imaging Cell Reports Methods 田翀（香港城市大学） 2. Enriched 10B-diboron reagents synthesis from 10BF3 Chem 刘超（中国科学院兰州化学物理研究所） 3. Fungal-induced fossil biomineralization Current Biology 罗茂（中国科学院南京地质古生物研究所） 4. Light modulates glucose metabolism by a retina-hypothalamus-brown adipose tissue axis Cell 薛天（中国科学技术大学） 5. SIM imaging resolves endocytosis of SARS-CoV-2 spike RBD in living cells Cell Chemical Biology 徐兆超（中国科学院大连化学物理研究所） 可持续发展领域 1. Electrocatalytic nitrate reduction to ammonia coupled with organic oxidation Chem Catalysis 邵明飞（北京化工大学） 2. Incorporating global change reveals extinction risk beyond the current Red List Current Biology 王志恒（北京大学） 3. Regional thermal environment changes: Integration of satellite data and land use/land cover iScience 杨俊（东北大学） 4. Risk of intact forest landscape loss goes beyond global agricultural supply chains One Earth 陈斌（复旦大学） 5. Visible-light-induced iron redox-catalyzed selective transformation of biomass into formic acid Chem 李洋（西安交通大学） 此外，为了支持实现性别平等和增强所有妇女和女孩的权能，细胞出版社特别设立的 Women in Science 奖项，今年评选出两位在科研界孜孜不倦并做出卓越贡献的女性科学家。 Women in Science 获奖名单 （排名不分先后） 陈玲玲 中国科学院分子细胞科学卓越创新中心 于吉红 吉林大学 获奖作者可扫描右侧二维码至中国科学家微站，领取获奖证书，并参与有奖互动！ ▌评审委员会（排名不分先后） 叶宇轩   西湖大学 丛    欢   中国科学院理化技术研究所 彭书时   北京大学 张    川   北京大学 覃张才   中山大学 Jason Wong  香港大学 王佳伟   中国科学院上海生命科学研究院植物生理生态研究所 顾    臻   浙江大学 陆    俊   浙江大学 叶玉如   香港科技大学 朱    嘉    南京大学 徐通达   福建农林大学 陈立功   清华大学 何丹阳   西湖大学 周景峰  北京脑科学与类脑研究所 张永辉   清华大学 陈    崇   四川大学 周圣涛   四川大学 刘    玉   四川大学 袁钧英  中国科学院上海有机化学研究所生物与化学交叉研究中心 03 助力描绘中国科研地图 过去的一年里，中国学者与细胞出版社不仅为世界贡献了极具影响力的学术成果，还勾勒出了一张更加广阔精彩的中国科研地图。 如果按照第一完成单位，将细胞出版社 2023 年发表的中国论文分类，我们能够获得一张精彩的“高校科研地图”。根据统计，从 2020 年到 2023 年，在细胞出版社旗下期刊发文的中国高校、研究机构和企业数量稳步上升，2023 年的增长幅度再创新高，发文机构数较上一年增加了 25% 以上。 各大高校中，中山大学以 93 篇位列发表量第一，浙江大学以 85 篇的发表量位列第二，北京大学以 79 篇位列第三； 上海交通大学、清华大学、复旦大学、北京协和医学院、华中科技大学、中国科学技术大学、中南大学分别位列第四到第十。 值得关注的是，与上一年相比，16 所中国高校或研究机构 2023 年在细胞出版社旗下期刊发文量的增长在 3 倍或以上。发文量增幅最高的三所高校为徐州医科大学、香港城市大学、香港大学。值得关注的是，增幅最高的 10 所机构中有 4 所为医科大学或医院，这从一个侧面展示出了细胞出版社对中国临床研究的重视与支持。 2023 年，中国科学院在细胞出版社旗下期刊发表了 267 篇论文，发文量较上一年增加 46.7%，“国家队”的中坚作用和特色优势尽显，其下各个创新中心和研究所的表现精彩纷呈。 从第一完成单位署名来看，中国科学院大连化学物理研究所发表的论文数量最多，为 20 篇；中国科学院动物研究所发表的论文数量次之，为 15 篇；中国科学院深圳先进技术研究院发表了 14 篇论文，排名第三。从涨幅来看，3 所研究院所在细胞出版社的发文量实现了 3 倍以上的增长，其中幅度最大的是中国科学院地理科学与资源研究所（增长 5 倍），中国科学院长春应用化学研究所、中国科学院植物研究所次之，发文量增长了 4 倍。 从论文第一通讯作者的地域分布来看，北京和上海以 423 和 284 篇的发表量稳居前两位，广东以 255 篇位列全国第三，江苏、浙江、湖北、香港、山东、福建、辽宁和安徽进入全国前十。值得关注的是，从增长幅度来看，香港、新疆、江西、重庆等地的发文量较上一年提升显著，其中香港发文量增幅为上一年的 32 倍，新疆和江西增幅分别为上一年的 2 倍和 1.6 倍。 根据全国科技经费投入统计公报的最新数字，2023 年我国研究与试验发展（R&D）经费投入强度超过全国平均水平的省（市）有 7 个，其中北京（6.73%）、上海（4.34%）、广东（3.54%）、江苏（3.29%）、浙江（3.20%）、安徽（2.69%） 6 个省（市）均在此次 2023 年发文量地域 TOP 10 的名单内，从侧面反映了国家经费投入对研究成果产出的积极影响。 04 百花齐放的国际合作 2023 年，中国学者持续活跃在世界舞台。与上一年相比，中国学者参与的国际合作论文总量继续保持增长势头。美国仍是与中国科学家合作最多的国家，也是最主要的合作国，两国学者一共合作发表了 516 篇论文。此外，英国、德国、加拿大、新加坡、澳大利亚、日本的学术机构与中国学者的合作论文数量均超过了 50 篇。 令人欣喜的是，在细胞出版社发表的国际合作论文中，2023 年中国学者合作的国家和地区数量达到了 90 个，同比增幅 23.3%，为 2019 年来最高。中国科学家与细胞出版社正在以开放的态度与世界各国学者携手共进。 05 Cell 与中国科学家，共同的 50 周年 Cell Press细胞出版社很荣幸地与“全球科学 50 人”（50 Scientists that Inspire）中的胡小玉教授、季维智院士、唐智勇院士和闵杰教授进行了深入对话。 1974 年，第一期 Cell 在美国诞生。今年，这本以发表“令人兴奋的生物学研究”为宗旨的知名期刊迎来了 50 岁生日。作为细胞出版社的一部分，今天的 Cell 是跨越多学科领域的近 60 种期刊之一，以热情和诚信吸引和支持所有学科的学者和从业者。 Cell 经历的 50 年，也是世界科学飞速发展的 50 年。一些在新一期 Cell 上发表的研究成果，其领域在 50 年前甚至 10 年前都还不存在或刚起步，比如碱基编辑、神经免疫学、HIV 疫苗开发和癌症免疫学。此外，从人工智能、海量科学文献的快速增长，到分享、评估和交流科学研究的各种方式，以及社交媒体等等，也为科学界带来了挑战。 值此良机，细胞出版社根据旗下各科学期刊的提名，在全球范围内评选出了 50 位推动创新、跨越科学界限、启迪未来的科学家——“全球科学 50 人”（50 Scientists that Inspire），共有 9 位获得这一称号的科学家来自中国！他们的研究工作和职业生涯推动了创新，跨越了学科界限，并激励着未来的领导者。这其中，既有关心学术领域性别平等的女科学家，也有工程学科出身却被生物学吸引的多背景学者，还有科研-产业两手抓的创新人才： 清华大学免疫研究所所长、免疫学家胡小玉因“揭示免疫细胞对微生物和炎症线索做出反应的机制”入选。她鼓励年轻科学家勇敢无畏地开展科研活动，并强调了解决科学领域性别不平等问题的必要性。 西湖大学生命科学学院讲席教授朱听，因“在镜像生物学和人工生命系统领域的前瞻性工作”入选。他将“镜像生物学”这个新名词带入公众视野，并与细胞出版社分享了他如何找到事业方向与人生意义的宝贵体验。 武汉大学高等研究院教授、材料科学家闵杰因“在有机太阳能电池稳定性方面的基础性研究”入选。他致力于提高有机太阳能电池的效率、稳定性和成本效益，不但拥有丰富的学术生涯，还授权了多项发明技术专利，并且是一家初创公司的联合创始人。 此外，Cell 还在 2024 年推出了一系列特别内容，从细胞生物学开始，重点介绍一系列新的和成熟的研究主题。此外，还与生命科学、医学、应用科学和物质科学等领域的姊妹期刊，在内容、倡议和活动方面达成了诸多合作。 正如 Cell 主编 John Pham 博士在 50 周年纪念社论中所说：“回望过去五十载，科学飞速发展、‘令人兴奋的生物学研究’层出不穷，令人目不暇接。……可以预见的是，科学研究将继续发生变化，有时甚至是变革，且其方式是今时今日的我们所难以想象的。……Cell 将继续分享各种声音、观点和视角，帮助解决这些问题。我们将找到创新方法，利用我们的平台架起沟通和联系的桥梁。” 开物成务，启智求真。细胞出版社将与中国科研相伴下一个 50 年，见证更多振奋人心的研究诞生。 备注：本文由“环球科学科研圈”根据细胞出版社（Cell Press）提供的数据及相关信息撰写，数据分析及可视化由“科研圈”完成，内容仅代表细胞出版社观点。凡本公众号转载、引用的文章、图片、音频、视频文件等资料的版权归版权所有人所有，如因此产生相关后果，将由版权所有人、原始发布者和内容提供者承担，如有侵权请尽快联系删除。

GE HealthCare’s FDA-approved flurpiridaz F 18 PET radiotracer, Flyrcado, delivers higher diagnostic efficacy in patients with known or suspected coronary artery disease (CAD), compared to SPECT MPI, the predominant procedure used in nuclear cardiology today With a half-life over ten times longer than currently approved cardiac PET radiotracers, Flyrcado brings the first practical opportunity to combine exercise stress testing with cardiac PET imaging for CAD Available as a unit dose - or ready-to-use, Flyrcado has the potential to expand clinician and patient access to PET myocardial perfusion imaging (MPI) ARLINGTON HEIGHTS, Ill.--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of Flyrcado™ (flurpiridaz F 18) injection, a first of its kind positron emission tomography myocardial perfusion imaging (PET MPI) agent, for the detection of coronary artery disease (CAD). Indicated for patients with known or suspected CAD, Flyrcado delivers higher diagnostic efficacy compared to single-photon emission computed tomography (SPECT) MPI, the predominant procedure used in nuclear cardiology today. Flyrcado, which can be manufactured in an offsite pharmacy and delivered as a ready-to-use unit dose, has the potential to expand clinician and patient access to PET MPI, including improving diagnostic accuracy in difficult-to-image patients such as those with a high body mass index (BMI) and women 1 . With a half-life of 109-minutes—significantly longer than existing PET MPI tracers—Flyrcado removes the need for on-site tracer production and generator maintenance and enables distribution to a wide network of hospitals and imaging centers. This longer half-life also means Flyrcado brings the first practical opportunity to combine exercise stress testing with cardiac PET imaging for CAD, enabling the most robust protocol for evaluating ischemia in patients. Furthermore, clinicians would have the ability to rescan a patient during the same imaging session in the event of technical difficulties, rather than rescheduling an additional scan. Dr. Jamshid Maddahi, MD, FACC, MASNC, principal investigator of the Flyrcado clinical trials, clinical professor of medicine (cardiology) and molecular and medical pharmacology (nuclear medicine) at UCLA School of Medicine and director of the Biomedical Imaging Institute, said, “Flyrcado is the most exciting development in the field of nuclear cardiology over the past few decades. Although PET MPI as a modality enables high diagnostic accuracy as compared to SPECT MPI 2 , only a minority of annual PET scans in the US are PET MPI because of limited access to the currently available PET tracers—which may be addressed with the introduction of Flyrcado. I am excited for this new radiotracer and its potential impact, as a game changer, for diagnosing the disease with the highest mortality rate in the world.” CAD is the most common form of heart disease and remains the leading cause of death for men and women in the U.S. 3 , with 695,000 deaths recorded in 2021 4 . During the multicenter international AURORA Phase III trial, flurpiridaz F 18 was compared with both invasive coronary angiography as a standard of truth to determine diagnostic efficacy in detecting CAD, as well as with SPECT MPI. Around six million MPI procedures are undertaken each year in the U.S. 5 to show blood flow through the heart muscle, and evaluate the presence, extent and degree of myocardial ischemia or infarction. Dr. Mouaz Al-Mallah, MD, MSc, MASNC, immediate Past President of the American Society of Nuclear Cardiology (ASNC) and Director of Cardiac PET at Houston Methodist Hospital, said “Given the desirable properties of flurpiridaz F 18, both in terms of myocardial uptake and fluorine-18 imaging characteristics, Flyrcado represents a favorable combination of imaging agent pharmacology and convenience to imaging institutions and patients. There are new frontiers for cardiac PET that this tracer can achieve; it can be ordered as a unit dose, and it offers the flexibility to perform exercise stress testing. We expect new imaging centers to be able to offer cardiac PET to their patients, making it more convenient to access PET MPI and providing a meaningful impact for clinicians and their patients.” Kevin O’Neill, CEO of the Pharmaceutical Diagnostics (PDx) segment of GE HealthCare, said, “As the first and only FDA-approved F 18 PET MPI radiotracer for CAD detection, Flyrcado can make a real difference to clinicians and their patients. This is another example of GE HealthCare’s commitment to innovating and investing to shape the future of molecular imaging, increasing diagnostic confidence and addressing unmet patient needs.” Flyrcado is one of three F 18 imaging agents in GE HealthCare’s portfolio of FDA-approved molecular imaging PET products, joining radiopharmaceutical PET imaging agents Cerianna™ (fluoroestradiol F 18) injection, used to detect estrogen receptor positive lesions as an adjunct to biopsy in patients with metastatic and recurrent breast cancer, and Vizamyl™ (flutemetamol F 18) injection which is a PET tracer for imaging of the brain to estimate beta amyloid neuritic plaque density in adult patients who are being evaluated for Alzheimer’s disease or other causes of cognitive decline. GE HealthCare acquired exclusive global commercialization rights for flurpiridaz F 18 from Lantheus in 2017 and has led the funding and development of the product through to approval. Lantheus collaborated on the development and will also collaborate on commercialization through a joint steering committee. Lantheus is entitled to royalties based on commercial sales milestones. Flyrcado will be available in initial U.S. markets in early 2025 with expanding availability thereafter. As a leading global medical technology and pharmaceutical diagnostics innovator, GE HealthCare provides both molecular imaging equipment and proprietary radiopharmaceuticals used across cardiology, neurology and oncology. The PDx segment is a global leader in imaging agents used to support over 120 million patient procedures per year globally, equivalent to four patient procedures every second. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits. Follow us on LinkedIn , X , Facebook , Instagram , and Insights for the latest news, or visit our website for more information. INDICATIONS AND USAGE OF FLYRCADO™: FLYRCADO™ (flurpiridaz F 18) injection, for intravenous use important safety information IMPORTANT SAFETY INFORMATION Indications and Usage FLYRCADO is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction. Contraindications None Warnings and Precautions Risk associated with exercise or pharmacologic stress: Patients evaluated with exercise or pharmacologic stress may experience serious adverse reactions such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, stroke, and seizure. Perform stress testing in the setting where cardiac resuscitation equipment and trained staff are readily available. When pharmacologic stress is selected as an alternative to exercise, perform the procedure in accordance with the pharmacologic stress agent’s prescribing information. Radiation risks: FLYRCADO contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to minimize radiation exposure to patients and health care providers. Advise patients to hydrate before and after administration and to void. Adverse Reactions Most common adverse reactions occurring during FLYRCADO PET MPI under rest and stress (pharmacologic or exercise) (incidence ≥ 2%) are dyspnea, headache, angina pectoris, chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia. Use in Specific Populations Pregnancy There are no data on use of flurpiridaz F 18 in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. If considering FLYRCADO administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from flurpiridaz F 18 and the gestational timing of exposure. FLYRCADO contains ethanol (a maximum daily dose of 337 mg anhydrous ethanol). If considering FLYRCADO administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes associated with ethanol exposure during pregnancy. Lactation Temporarily discontinue breastfeeding. A lactating woman should pump and discard breastmilk for at least 8 hours after FLYRCADO administration. Pediatric Use Safety and effectiveness of FLYRCADO in pediatric patients have not been established. To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800-654-0118 (option 2 then option 1) or by email at GPV.drugsafety@gehealthcare.com or FDA at 800-FDA-1088 or For full prescribing information, click here . For important safety information, please click here . INDICATIONS AND USAGE OF CERIANNA™: INDICATIONS AND USAGE CERIANNA is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. Limitations of Use Tissue biopsy should be used to confirm recurrence of breast cancer and to verify ER status by pathology. CERIANNA is not useful for imaging other receptors, such as human epidermal growth factor receptor 2 (HER2) and the progesterone receptor (PR). CONTRAINDICATIONS None. ADVERSE REACTIONS In Clinical Trials (n=1207) the most common adverse reactions seen occurred at a rate < 1% were injection-site pain and dysgeusia. To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare Company at 800.654.0118 (option 2 then option 1) or by email at GPV.drugsafety@gehealthcare.com or FDA at 1-800-FDA-1088 or . For full Prescribing Information click here . INDICATIONS AND USAGE OF VIZAMYL™: PRODUCT INDICATIONS AND USE VIZAMYL™ (Flutemetamol F 18) injection is indicated for positron-emission tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) or other causes of cognitive decline. A negative scan indicates sparse to no neuritic plaques, inconsistent with a diagnosis of AD at the time of image acquisition. A negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive scan indicates moderate to frequent amyloid neuritic plaques. This amount of amyloid neuritic plaque has been shown to be present in patients with AD but may also be present in patients with other neurologic conditions as well as in older people with normal cognition. Vizamyl is an adjunct to other diagnostic evaluations. Limitations: A positive scan does not establish a diagnosis of AD or other cognitive disorder. The safety and effectiveness of Vizamyl have not been established for predicting the development of dementia or other neurologic conditions or for monitoring responses to therapies. Important Safety Information About VIZAMYL ™ (Flutemetamol F 18) injection CONTRAINDICATIONS • Known hypersensitivity to Vizamyl or any excipient, including polysorbate 80 ADVERSE REACTIONS • The most commonly reported adverse reactions in clinical trials were flushing (2%), increased blood pressure (2%), headache (1%), nausea and dizziness (1%) For full prescribing information, including additional important safety information, please click here . 1 Maddahi J, Agostini D, Bateman TM, Bax JJ, Beanlands RSB, BermanDS, Dorbala S, Garcia EV, Feldman J, Heller GV, Knuuti JM, Martinez-Clark P, Pelletier-Galarneau M, Shepple B, Tamaki N, Tranquart F, Udelson JE. Flurpiridaz F-18 PET Myocardial Perfusion Imaging in Patients with Suspected Coronary Artery Disease. J AmColl Cardiol. 2023; 82:1598–1610 2 Schindler, T. H., Bateman, T. M., Berman, D. S., Chareonthaitawee, P., De Blanche, L. E., Dilsizian, V., Dorbala, S., Gropler, R. J., Shaw, L., Soman, P., Winchester, D. E., Verberne, H., Ahuja, S., Beanlands, R. S., Di Carli, M. F., Murthy, V. L., Ruddy, T. D., & Schwartz, R. G. (2020). Appropriate use criteria for PET myocardial perfusion imaging. Journal of Nuclear Medicine, 61 (8), 1221-1265. 3 Friede A, O’Carroll PW, Thralls RB, Reid JA. CDC WONDER on the web. Proc AMIA Annu Fall Symp. 1996:408–412. 4 Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics—2023 update: A report from the American Heart Association. Circulation. 2023;147: e93–e621. . 5 Miller, R. J. H., Bednarski, B. P., Pieszko, K., Kwiecinski, J., Williams, M. C., Shanbhag, A., Liang, J. X., Huang, C., Sharir, T., Hauser, M. T., Dorbala, S., Di Carli, M. F., Fish, M. B., Ruddy, T. D., Bateman, T. M., Einstein, A. J., Kaufmann, P. A., Miller, E. J., Sinusas, A. J., Acampa, W., Han, D., Dey, D., Berman, D. S., & Slomka, P. J. (2024). Clinical phenotypes among patients with normal cardiac perfusion using unsupervised learning: A retrospective observational study. EBioMedicine , 99, 104930. Contacts GE HealthCare Media Contact: Emmy Elguizaoui +1 (978) 243-7503 Emmy.Elguizaoui@gehealthcare.com